Home

Targos News

The One Health Initiative:
Comparative Pathology

The “One Health initiative” www.onehealthinitiative.com fosters close interactions between physicians and veterinarians with the goal to further investigate neoplastic, nutritional and metabolic diseases, environmental health threats and zoonotic diseases.

Comparative pathology:

Weiterlesen

One Health initiative

>

Targos & Ultivue

Targos and Ultivue partner to incorporate highly standardized UltiMapper™ tissue multiplex phenotypic assays in support of clinical research services.

Weiterlesen

Press Information

>

Predictive Biomarkers
in Oncology

Research and experience of Targos staff
- Published by Springer

20. February 2019
Targos is proud to present the new comprehensive Springer Nature publication Predictive Biomarkers in Oncology. Applications in Precision Medicine- edited by Sunil Badve, Indiana University and George Kumar, Targos Inc, co-authored by many international experts from academic, clinical, government (FDA, NCI), and industry background: demonstrating our network and expertise.

Weiterlesen

Press Information

>

Philips & Targos

Royal Philips (NYSE: PHG, AEX: PHIA) and Targos, today announced a joint initiative to enhance digital pathology education and help drive the global standardization of clinical biomarkers.

Weiterlesen

Press Information

>

31st European Congress of Pathology
- Pathology is Nice

Oral Presentations

1. Standardised structured training of pathologists to improve inter- and intra-reader reproducibility for scoring PD-L1 expression levels in non-small cell lung cancer: results of a worldwide training programme.
2. Digital microscopy - is there a need for standardisation?
3. High reproducibility of PD-L1 scoring among pathologists participating in live trainings.

Poster Presentations

Prof. Reinhard Büttner:
• Genomic profiling for driver mutations in cancer: NTRK gene fusions (Bayer)
• LS-09 From respectable to exceptional: advancing beyond existing PD-L1 test capabilities for histologic and cytologic NSCLC specimens (AstraZeneca)
Prof. Bharat Jasani:
• Strategies for addressing the intrinsic source of error associated with PD-L1 scoring and interpretation.

Weiterlesen

September 7 - 11 , 2019 | Nice, France

>

Targos offers PD-L1 training

In addition, we also provide PD-L1 testing services within clinical trials utilizing currently commercially available PD-L1 IVD assays (SP142, SP263, 22C3, 28-8) validated in a fully CAP/CLIA compliant environment.

Weiterlesen

Testing at Targos

PD-L1

>

TARGOS Molecular Pathology GmbH

  +49 561-50045299      +49 561-50045355      info@targos-gmbh.de

Contact Us

Main Lab and Office

We will be happy to meet you!

Contact us

Get in touch